Clomipramine is NOT recommended for patients with comorbid bipolar mania and severe OCD
In patients with comorbid bipolar disorder and OCD, SSRIs should be used with caution or avoided, and clomipramine specifically carries significant risk of inducing mania—mood stabilization must be the primary treatment goal before considering any serotonergic agent. 1
Treatment Algorithm for BD-OCD Comorbidity
Step 1: Establish Mood Stability First
The most recent OCD treatment guideline explicitly states that SSRIs should not be recommended or should be used with caution in patients with comorbid bipolar disorder 1. This applies even more strongly to clomipramine, which is a potent serotonin reuptake inhibitor with documented risk of precipitating mania.
Primary treatment should consist of:
- Mood stabilizers (lithium, valproate) and/or
- Atypical antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine) 2
The guideline specifically notes that "the presence of specific comorbidities may change the algorithm (for example, focus on mood stabilizers plus CBT in the presence of bipolar disorder)" 1.
Step 2: Address OCD Only After Mood Stabilization
Once mania is controlled with mood stabilizers:
- Cognitive behavioral therapy (CBT) with exposure and response prevention (ERP) should be the preferred treatment for OCD symptoms 1
- The systematic review evidence shows that 42.1% of BD-OCD patients required multiple mood stabilizers, and only in rare cases did addition of antidepressants lead to remission of both conditions 3
Step 3: Consider SRIs Only for Refractory OCD
If OCD symptoms persist despite adequate mood stabilization and CBT:
- SRIs may be added at the lowest feasible dose 4
- However, clomipramine carries particularly high risk given multiple case reports of clomipramine-induced mania in OCD patients 5, 6
Critical Safety Concerns with Clomipramine in Bipolar Disorder
Clomipramine has documented risk of inducing manic episodes in OCD patients, even those without known bipolar disorder 5, 6. In patients with established bipolar mania, this risk is substantially amplified. Case series demonstrate that antidepressants (including clomipramine) can induce mood instability, and improvement only occurred after discontinuation and initiation of mood stabilizers 4.
Common Pitfalls to Avoid
- Do not prioritize OCD treatment over mood stabilization—this leads to worsening mania and treatment failure
- Do not assume that treating OCD will improve overall functioning if mania is uncontrolled—the bipolar disorder must be addressed first
- Do not use clomipramine as first-line even for severe OCD when bipolar disorder is present—the FDA label for clomipramine does not address bipolar comorbidity as a specific indication, and the risk-benefit ratio is unfavorable 7
Evidence Quality Assessment
The 2019 Nature Reviews Disease Primers guideline 1 provides the most authoritative and recent guidance, explicitly cautioning against SSRIs/SRIs in bipolar disorder. This is supported by a 2014 systematic review 3 showing that mood stabilization alone was sufficient in most BD-OCD cases, with SRIs being unnecessary or even detrimental. The convergence of guideline recommendations, systematic review data, and multiple case reports of clomipramine-induced mania 5, 6 creates a clear clinical directive against using clomipramine in this population.